What FDA’s PCAC Meeting Revealed About the Future of Peptides Compounding

Beyond the Vote: The Standards of Shaping the Future of Peptide Compounding

Over two days, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) evaluated seven peptide-related bulk drug substances, BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Epitalon, and Semax, for potential inclusion on the 503A Bulks List. Beyond the recommendations, the meeting revealed the standards likely to shape the future of peptide compounding: clear ingredient identity, pharmaceutical quality, credible scientific rationale, and responsible patient access.

Access Is Only the Beginning

For more than 37 years, Medisca has operated on a clear principle: the quality of a compounded preparation begins with the quality of the active pharmaceutical ingredient behind it.

That means knowing who manufactured the ingredient, how the supplier was qualified, how the material was characterized and tested, and whether the documentation and supply chain provide the level of confidence a pharmacist requires.

Those questions were central to the FDA PCAC’s two-day meeting on seven peptide-related bulk drug substances nominated for inclusion on the 503A Bulks List.

Although the committee considered each substance individually, its discussions revealed a broader direction for peptide compounding. Access remains important, but access alone will not determine the future of the category. The scientific evidence, pharmaceutical controls, supplier accountability, and ingredient transparency supporting that access will matter just as much. 

Committee recommendations at a glance

The advisory committee considered the free-base and acetate forms of each peptide-related bulk drug substance as separate entries. The voting outcomes were identical for both forms; therefore, the recommendations are summarized by peptide in the table below.

These recommendations are advisory. They do not constitute FDA approval or a final Agency decision but will inform the FDA’s broader evaluation of whether each substance should be included on the 503A Bulks List.

 

Peptide	Recommendation	Key Discussion Themes
BPC-157	Recommended for Inclusion	Scientific evidence, API characterization, patient need
KPV	Recommended for Inclusion	Ingredient quality, scientific rationale
TB-500	Recommended for Inclusion	Identity, evidence, appropriate use
MOTS-c	Recommended for Inclusion	Characterization, patient access
Emideltide (DSIP)	Not recommended for inclusion	Characterization, limited clinical evidence
Semax	Recommended for Inclusion	API Identity and characterization, clinical evidence, patient access
Epitalon	Recommended for Inclusion	Characterization and nomenclature, impurities, clinical evidence, manufacturing standards

 

What the Meeting Revealed

The individual recommendations will attract attention. The more significant outcome, however, was the framework that emerged from the committee's discussions.

Across the seven substances, committee members consistently returned to four questions:

1. Is the bulk drug substance sufficiently identified and characterized? 
2. What scientific evidence supports its proposed use? 
3. Can the ingredient be produced and supplied with appropriate pharmaceutical controls? 
4. Is there a legitimate patient need that compounding may help address? 

These are some of the same fundamentals that have shaped our approach for more than 37 years: rigorous supplier qualification, robust quality systems, ingredient transparency, and the documentation healthcare professionals need to make informed decisions with confidence. 

Clinical rationale cannot replace confidence in ingredient identity or consistency. A certificate of analysis alone cannot replace meaningful supplier qualification. Patient demand does not eliminate the need for rigorous documentation, manufacturing controls, and scientific evaluation.

The meeting reinforced a principle that has long guided responsible compounding:
Responsible access begins with a reliable ingredient.

Why API Quality Matters

For pharmacists, API quality has always mattered. What is changing is the level of scrutiny surrounding it.

Peptide-related substances can present complex questions involving structure, purity, stability, impurities, analytical methods, and batch-to-batch consistency. These are not simply scientific considerations; they directly influence confidence in the ingredients used to prepare patient-specific medications.

That confidence is built through:

• Qualified manufacturers and suppliers 
• Robust analytical testing and specifications 
• Traceable sourcing and supply chains 
• Complete documentation 
• Controlled transportation and storage 
• Effective quality systems 

This is what pharmaceutical quality looks like in practice.

It is not a claim made at the point of sale. It is a system of controls that begins long before an ingredient reaches the pharmacy.

For more than three decades, Medisca has invested in that system, qualifying suppliers, strengthening pharmaceutical supply chains, supporting analytical documentation, and providing the scientific and technical resources pharmacists rely on to compound with confidence.

The PCAC meeting, including testimony from key opinion leaders, physicians, and pharmacists, did not create these expectations. It reinforced the importance of quality assurance in supporting the safe supply of peptides to patients.

Access Requires Quality

Patient access remained an important part of the committee's discussion.

Compounded medications continue to play an important role in meeting legitimate patient-specific needs when prepared within the applicable legal and professional framework.

The meeting also reinforced that access and quality are not competing priorities. 

Responsible access begins with ingredients and systems worthy of the trust placed in them.

The long-term credibility of peptide compounding will depend on the profession's ability to pair patient need with qualified ingredients, sound science, appropriate quality systems, and professional judgment.

Looking Ahead

The committee’s recommendations now move to the FDA for further consideration and should not be interpreted as final authorization or a change in the regulatory status of any substance.

Regardless of the FDA’s final decisions, the meeting reinforced the standards Medisca has championed for more than 37 years: scientific rigor, pharmaceutical quality, ingredient transparency, qualified suppliers, and confidence in every active pharmaceutical ingredient used to prepare patient-specific medications.

Medisca remains committed to supporting pharmacists and clinicians with the pharmaceutical-quality ingredients, transparency, and expertise required to serve their patients responsibly.

The future of peptide compounding will not be defined by access alone, but by quality pharmacists can verify, clinicians can rely on, and patients can trust.